TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12161476

Group type: EXPERIMENTAL
Intervention: Daily hGH therapy (6 mg/m2 weekly)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Alternate day hGH therapy (6 mg/m2 weekly)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cumulative growth velocity over 4 years (2 years on and 2 years off therapy)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Adult height prediction after 4 years
Number of subjects: 38
Study: 10532694

Group type: EXPERIMENTAL
Intervention: Heparin infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 7762500

Group type: EXPERIMENTAL
Intervention: Monophasic waveform (Edmark)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Biphasic waveform (Gurvich)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Monophasic waveform (Edmark) for VF
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Biphasic waveform (Gurvich) for VF
Number of subjects: 171
Study: 2140030

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at the P6 point for 15 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at the P6 point for 15 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg intravenously
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 100
Study: 343862

Group type: EXPERIMENTAL
Intervention: 75Se‐labelled amino acids
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Two of the 75Se‐labelled amino acids
Number of subjects: 22
Study: 30664895

Group type: EXPERIMENTAL
Intervention: Radiation therapy with 6 months of androgen deprivation therapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Radiation therapy without androgen deprivation therapy
Number of subjects: 204
Study: 28612123

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27108466

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50
Study: 23402500

Group type: EXPERIMENTAL
Intervention: Primary infiltration of 1 cartridge of 4% articaine with 1:100,000 epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Repeat infiltration of 1 cartridge of 4% articaine with 1:100,000 epinephrine after 20 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mock repeat infiltration
Number of subjects: 100
Study: 22403979

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chlorhexidine digluconate (AlF3/Chx) dentifrice
Number of subjects: 28
Study: 19486077

Group type: EXPERIMENTAL
Intervention: Zirconia abutments
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 22
Study: 16289980

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 1000 microg bid
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral prednisone (P)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both FP and P
Number of subjects: 37
Study: 14695986

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxa treatment at therapeutic points
Number of subjects: 19

Group type: COMPARATOR
Intervention: Indifferent points (Control Group)
Number of subjects: 19
Study: 10870872

Group type: EXPERIMENTAL
Intervention: Zaleplon 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8818850

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg three times daily for 10 days)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 67
Study: 1430361

Group type: EXPERIMENTAL
Intervention: 15% paromomycin sulfate and 12% methylbenzethonium chloride (15/12 P-ointment)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 15% paromomycin sulfate and 5% methylbenzethonium chloride (15/5 P-ointment)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 39
Study: 6100870

Group type: EXPERIMENTAL
Intervention: Enalapril (10-40 mg q.d.)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Enalapril (10-40 mg q.d.) + Hydrochlorothiazide (50 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Enalapril (40 mg) + Hydrochlorothiazide (50, 25, 12.5 mg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Enalapril alone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Enalapril + Hydrochlorothiazide
Number of subjects: 53
Study: 31066883

Group type: EXPERIMENTAL
Intervention: PUVA induction regimen (12- to 24-week duration)
Number of subjects: 27
Study: 28766879

Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus 0.75 mg/kg followed by infusion of 1.75 mg/kg, extra bolus 0.3 mg/kg before stenting)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH, 100 IU/kg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bivalirudin and UFH
Number of subjects: 84
Study: 26382728

Group type: EXPERIMENTAL
Intervention: 560 mg oral ibrutinib, fasting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 560 mg oral ibrutinib, fed, after glucose drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 140 mg oral ibrutinib, fed, with grapefruit juice before dosing
Number of subjects: 0
Study: 24569887

Group type: EXPERIMENTAL
Intervention: HIV testing routines
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: STI testing routines
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Knowledge, beliefs, attitudes, subjective norms, perceived behavioral control
Number of subjects: 580
Study: 22572105

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Breast milk DHA
Number of subjects: 420
Study: 20190538

Group type: EXPERIMENTAL
Intervention: GnRHa combined with GH
Number of subjects: 46

Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TW3 method
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: GP method
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 46
Study: 18301927

Group type: EXPERIMENTAL
Intervention: Interbody fusion cage containing beta‐TCP with supplemented anterior plate (n = 33)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Interbody fusion cage containing beta‐TCP without supplemented anterior plate (n = 29)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (with and without plate fixation)
Number of subjects: 62
Study: 16507379

Group type: EXPERIMENTAL
Intervention: Switching from olanzapine to risperidone
Number of subjects: 121
Study: 12005275

Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 10220208

Group type: EXPERIMENTAL
Intervention: NN304 (0.15 U/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NN304 (0.3 U/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NN304 (0.6 U/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: NPH-insulin (0.3 U/kg)
Number of subjects: 11
Study: 8697123

Group type: EXPERIMENTAL
Intervention: Polyurethane foam hydrophilic dressing (Allevyn)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium sodium alginate dressing (Kaltostat)
Number of subjects: 0
Study: 1662885

Group type: EXPERIMENTAL
Intervention: Temafloxacin 200 mg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg
Number of subjects: 421

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg
Number of subjects: 421
Study: 7045975

Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid) given with food (TF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid) given without food (T)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bilopaque (sodium tyropanoate) given without food
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of Telepaque and Bilopaque (TF-B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of Telepaque given with food (TF) and Telepaque given without food (TF-TF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of Telepaque given without food (T) and Telepaque given without food (T-T)
Number of subjects: 15
Study: 31368269

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (Tamsulosin 0.2 mg/d for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (Tamsulosin 0.2 mg/d for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 60
Study: 29935972

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Anterolateral Approach (ALA)
Number of subjects: 30
Study: 25963332

Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT) with pneumatic and manual lymphatic drainage
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Quasi-Kinesiology Taping with pneumatic and manual lymphatic drainage
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard procedure - pneumatic and manual lymphatic drainage and multilayered bandaging
Number of subjects: 70
Study: 25182250

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 21943828

Group type: EXPERIMENTAL
Intervention: Preoperative education (usual care plus an information leaflet and verbal advice)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 153
Study: 20139678

Group type: EXPERIMENTAL
Intervention: DHA supplementation in infant formula for preterm infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA supplementation during pregnancy and/or lactation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA supplementation timing and dose
Number of subjects: 0
Study: 18341564

Group type: EXPERIMENTAL
Intervention: Lidocaine 20% patch (DentiPatch)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lidocaine 5% gel
Number of subjects: 31
Study: 16522892

Group type: EXPERIMENTAL
Intervention: PTFI (Pharmacist Telephone Follow-up Intervention)
Number of subjects: 255

Group type: COMPARATOR
Intervention: UPI (Usual Pharmacist Intervention)
Number of subjects: 255
Study: 12386637

Group type: COMPARATOR
Intervention: Fixed 800 mg/d ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body weight-based 800/1000/1200 mg/d ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 13 mg/kg per day ribavirin
Number of subjects: 0
Study: 10442910

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 5342

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 5342
Study: 7561805

Group type: EXPERIMENTAL
Intervention: PM vaccine (Pasteur Mérieux)
Number of subjects: 839

Group type: COMPARATOR
Intervention: SKB vaccine (Smith‐Kline Beecham)
Number of subjects: 839
Study: 2140854

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg loading dose: 4 mg IV plus 4 mg orally, followed by 8 mg every 8 hours orally for 3 to 5 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Metoclopramide (80 mg loading dose: 60 mg IV plus 20 mg orally, followed by 20 mg every 8 hours orally for 3 to 5 days)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 75

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 75
Study: 443500

Group type: EXPERIMENTAL
Intervention: Physician prescribed exercise with health education
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 124
Study: 30569245

Group type: EXPERIMENTAL
Intervention: AB928 (10 to 200 mg once daily and 100 mg twice daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 29275794

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 22
Study: 23835673

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil (1 μg/kg)
Number of subjects: 60
Study: 23507173

Group type: COMPARATOR
Intervention: 0 g GOS (Control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 5 g GOS
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 g GOS
Number of subjects: 31
Study: 21205361

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural body image therapy (10 group sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 32
Study: 19667282

Group type: EXPERIMENTAL
Intervention: 6-month therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: 9-month therapy
Number of subjects: 90
Study: 17464696

Group type: EXPERIMENTAL
Intervention: Five SNPs (rs2494732, rs2498799, rs3730358, rs1130214, rs3803300)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Five-SNP haplotypes
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Five domain scores (processing speed, reasoning, verbal memory, working memory, vigilance)
Number of subjects: 641
Study: 15276392

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/day) + Clopidogrel (75 mg/day)
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/day) alone
Number of subjects: 7599
Study: 11689577

Group type: EXPERIMENTAL
Intervention: Capecitabine 1,250 mg/m² administered twice daily days 1 to 14 every 3 weeks
Number of subjects: 602

Group type: COMPARATOR
Intervention: Intravenous 5-FU plus leucovorin (5-FU/LV)
Number of subjects: 602
Study: 10774973

Group type: EXPERIMENTAL
Intervention: Randomly alternating imaging conditions (y-axis inverted and normal laparoscopic)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Full binocular imaging
Number of subjects: 32

Group type: COMPARATOR
Intervention: Y-axis inverted imaging
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal laparoscopic imaging
Number of subjects: 32
Study: 8944406

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0
Study: 1280737

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 57
Study: 6424854

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31078146

Group type: EXPERIMENTAL
Intervention: M1E1, M1E5, M5E3, M5E4, M5E5 primer combinations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M5E1 primer pair
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M4E4 primer combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M2E3 primer combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M4E3 primer combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M2E5, M4E1, M5E1 primer combinations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M3E1 primer combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M2E1, M2E2, M4E1, M5E3 primer combinations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M2E4 primer combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M1E5, M2E2, M3E2 primer combinations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: M1E2, M2E3, M5E5 primer combinations
Number of subjects: 13
Study: 29873529

Group type: EXPERIMENTAL
Intervention: HTX-019 130 mg (30-min infusion)
Number of subjects: 200

Group type: COMPARATOR
Intervention: fosaprepitant 150 mg (20- or 30-min infusion)
Number of subjects: 200
Study: 26395352

Group type: EXPERIMENTAL
Intervention: 38% Silver diamine fluoride (SDF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study: 24472331

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral midazolam
Number of subjects: 108
Study: 22488208

Group type: EXPERIMENTAL
Intervention: Sugar-free gum with casein phosphopeptide amorphous calcium phosphate (CPP-ACP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar-free gum without CPP-ACP
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-gum control
Number of subjects: 0
Study: 20081109

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.7 pmol.kg(‐1).min(‐1))
Number of subjects: 20
Study: 17700437

Group type: EXPERIMENTAL
Intervention: Disc prosthesis
Number of subjects: 49

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 49
Study: 16231625

Group type: EXPERIMENTAL
Intervention: Closed CPB system with aspiration of blood from the operation field via the cardiotomy suction line and active venting of the heart via a roller pump
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed CPB system avoiding aspiration of blood from the operation field via the cardiotomy suction line, but with active venting of the heart
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed system, avoidance of aspiration of blood from the operation field via the cardiotomy suction line and with passive venting of the heart into the collapsible venous reservoir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Avoidance of aspiration of blood via the cardiotomy suction line
Number of subjects: 0
Study: 11867385

Group type: EXPERIMENTAL
Intervention: IV clonidine (3 microg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 29
Study: 10372584

Group type: EXPERIMENTAL
Intervention: H&P-first group
Number of subjects: 315

Group type: COMPARATOR
Intervention: H&P-last group
Number of subjects: 315
Study: 7832347

Group type: EXPERIMENTAL
Intervention: Videotape group (received the 10-minute CPR instruction videotape)
Number of subjects: 8659

Group type: COMPARATOR
Intervention: No-videotape group (did not receive the videotape)
Number of subjects: 8659

Group type: EXPERIMENTAL
Intervention: Individuals who watched the videotape during cardiac arrests
Number of subjects: 8659
Study: 1973387

Group type: EXPERIMENTAL
Intervention: Propranolol (PROP)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol (MET)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study: 31622684

Group type: EXPERIMENTAL
Intervention: Patient portal usage
Number of subjects: 301
Study: 31189674

Group type: EXPERIMENTAL
Intervention: QCPR Classroom
Number of subjects: 642

Group type: COMPARATOR
Intervention: Standard CPR training (Control)
Number of subjects: 642
Study: 27885247

Group type: EXPERIMENTAL
Intervention: Psychoeducational website (UTSMed) providing mental health literacy and cognitive behavioral skills; duration not specified.
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control group (no intervention); duration not specified.
Number of subjects: 313
Study: 26540491

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 or 5 μg
Number of subjects: 6966

Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 μg
Number of subjects: 6966
Study: 23913464

Group type: EXPERIMENTAL
Intervention: Rhythm control strategy (antiarrhythmic medication and/or electrical cardioversion)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 413
Study: 21445603

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) resistance exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) resistance exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-Intensity Blood Flow Restricted (LI-BFR) resistance exercise
Number of subjects: 11
Study: 19736281

Group type: COMPARATOR
Intervention: Therapeutic interventions
Number of subjects: 167

Group type: COMPARATOR
Intervention: Trials without exclusions
Number of subjects: 167
Study: 17090821

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cell therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (PCI only)
Number of subjects: 45
Study: 15001902

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 0.25 mg/kg on cardiopulmonary bypass
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no phenoxybenzamine)
Number of subjects: 71
Study: 11722291

Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques (ACBT) assisted by a physiotherapist
Number of subjects: 15

Group type: COMPARATOR
Intervention: Active cycle of breathing techniques (ACBT) performed independently by the patient
Number of subjects: 15
Study: 9374816

Group type: EXPERIMENTAL
Intervention: High hydration (HighH) - 2.0 ml water/kg body weight every 30 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low hydration (LowH) - 0.25 ml water/kg body weight every 30 min
Number of subjects: 8
Study: 7695068

Group type: EXPERIMENTAL
Intervention: Enzyme‐linked immunosorbent assay (ELISA) for measuring IgG subclasses
Number of subjects: 317

Group type: COMPARATOR
Intervention: Radial immunodiffusion (RID) methods
Number of subjects: 317
Study: 3539523

Group type: EXPERIMENTAL
Intervention: PEEP titration based on PaO2 < 65 torr with FIO2 of 0.45
Number of subjects: 38

Group type: COMPARATOR
Intervention: PEEP titration until PaO2/FIO2 > 300 or Qsp/Qt < 0.20
Number of subjects: 38
Study: 30474216

Group type: EXPERIMENTAL
Intervention: rhDNase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28603468

Group type: EXPERIMENTAL
Intervention: Formulated milk product containing 9 g milk protein (FMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoenergetic carbohydrate placebo (CHO)
Number of subjects: 20
Study: 25058380

Group type: EXPERIMENTAL
Intervention: Live related limbal allograft (Lr‐CLAL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cadaveric keratolimbal allograft (KLAL)
Number of subjects: 20